Home Stock

Stock Research: Innoviva

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Innoviva

NSQ:INVA US45781M1018
83
  • Value
    91
  • Growth
    34
  • Safety
    Safety
    92
  • Combined
    83
  • Sentiment
    67
  • 360° View
    360° View
    83
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Innoviva, Inc. is a diversified holding company focused on healthcare assets. It operates in the healthcare industry, with a portfolio of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA. It also has products like GIAPREZA and XERAVA. The company is based in the United States. In the last fiscal year, the company had a market cap of $1,257 million, profits of $322 million, revenue of $359 million, and 127 employees.

more

ANALYSIS: With an Obermatt 360° View of 83 (better than 83% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Innoviva are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Innoviva. The consolidated Value Rank has an attractive rank of 91, which means that the share price of Innoviva is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 91% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 92. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 67. But the consolidated Growth Rank has a low rank of 34, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 66 of its competitors have better growth. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country USA
Industry Pharmaceuticals
Size Medium
Website inva.com
Index
NASDAQ
Innoviva stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
91 43 14 53
Growth
34 31 57 21
Safety
Safety
92 57 60 87
Sentiment
67 36 29 61
360° View
360° View
83 23 21 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
21 15 1 2
Opinions Change
50 50 50 50
Pro Holdings
n/a 86 98 98
Market Pulse
65 31 20 60
Sentiment
67 36 29 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
91 43 14 53
Growth
34 31 57 21
Safety Safety
92 57 60 87
Combined
83 25 31 64
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
58 34 24 20
Price vs. Earnings (P/E)
82 70 50 89
Price vs. Book (P/B)
74 45 41 64
Dividend Yield
1 1 1 1
Value
91 43 14 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
76 17 49 9
Profit Growth
9 8 15 30
Capital Growth
57 72 71 23
Stock Returns
43 67 77 87
Growth
34 31 57 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
39 41 30 50
Refinancing
86 42 55 41
Liquidity
88 78 85 94
Safety Safety
92 57 60 87

Similar Stocks

Discover high‑ranked alternatives to Innoviva and broaden your portfolio horizons.

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews